Personalized medicine is creating quite a revolution of sorts. A clue into what might be the norm, years from now, personalized medicines will aim at reducing or totally obliterating the side-effects by evolving medicines that are tailor -made to a person's genetic information. Indeed this will be a whole new story in the development of drugs.
Amalia M. Issa, a pharmacologist and clinical epidemiologist is the director of the Program in Personalized Medicine and Targeted Therapeutics at the Abramson Family Center for the Future of Health, a joint initiative between UH and The Methodist Hospital Research Institute. The discussion on personalized medicine will focus on initiatives to develop drugs that are customized for an individual patient's particular condition and side-effects profile, and the process required for innovative pharmaceuticals. The main issues facing the scientists and pharmaceutical industry will also receive focus during the discussion.